საკვანძო სიტყვები
MASH
Lifestyle
Pharmacological interventions
Liver disease
Obesity
Type 2 diabetes
როგორ უნდა ციტირება
ანოტაცია
Background & aim: Metabolic Dysfunction-Associated Fatty Liver Disease, a common condition linked to the global epidemics of obesity and type 2 diabetes, is a major health concern. The condition can progress from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma. Currently, there is no universal cure and disease prevention strategies are the primary focus. The main treatment approaches are lifestyle changes and pharmacological interventions. The aim of the study was to compare these two strategies, assessing their mechanisms, efficacy, safety and clinical utility.
Methods: The systematic review was conducted by combining and evaluating data from range of peer-reviewed scientific publications, including clinical trials, systematic reviews and meta-analyses, comprising a total of 10 studies and 1987 patients. The data was categorized using two primary treatment modalities: Lifestyle changes (interventions like weight loss, specific dietary patterns and physical activity) and pharmacological interventions (Pioglitazone, Liraglutide (GLP1 agonist) and Vitamin E). Each approach was evaluated for its ability to improve liver histology, reduce liver fat and resolve MASH.
Results & Conclusion: Lifestyle interventions, particularly structured dietary modifications and regular physical activity, consistently demonstrated significant reductions in hepatic steatosis, improvement in insulin sensitivity, and, in some cases, regression of fibrosis. Pharmacological agents such as pioglitazone, vitamin E, and GLP-1 receptor agonists provided histological and metabolic benefits, with pioglitazone improving fibrosis, vitamin E reducing oxidative stress and inflammation, and GLP-1 agonists contributing to weight loss and metabolic improvement. While pharmacological agents offer targeted benefits, lifestyle interventions proved more sustainable and broadly effective across populations.
წყაროები
Sangro P, de la Torre Aláez M, Sangro B, D'Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. J Physiol Biochem. 2023 Nov;79(4):869-879. doi: 10.1007/s13105-023-00954-4.
Chai X-N, Zhou B-Q, Ning N, Pan T, Xu F, He S-H, Chen N-N and Sun M (2023) Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis. Front. Endocrinol. 14:1081096. doi: 10.3389/fendo.2023.1081096
Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of Obesity in Adults: Latest Trends. Curr Obes Rep. 2018 Dec;7(4):276-288. doi: 10.1007/s13679-018-0317-8. PMID: 30155850; PMCID: PMC6215729.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.
Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016.
Semmler G, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD/NASH: Beyond the obvious. Liver Int. 2021 Oct;41(10):2249-2268. doi: 10.1111/liv.15024.
Ristic-Medic, D.; Kovacic, M.; Takic, M.; Arsic, A.; Petrovic, S.; Paunovic, M.; Jovicic, M.; Vucic, V. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. Nutrients2021, 13, 15. https://doi.org/10.3390/nu13010015
Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, Miele L, Giannini EG. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients. 2019 Dec 5;11(12):2971. doi: 10.3390/nu11122971.
Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci. 2019 Aug;19(7):994-1003. doi: 10.1080/17461391.2019.1571114.
Machado MV. Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. Diabetes Metab Syndr Obes. 2021 Aug 11;14:3627-3645. doi: 10.2147/DMSO.S304357.
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307. doi: 10.1056/NEJMoa060326.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675-1685 DOI: 10.1056/NEJMoa0907929
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003 Nov;98(11):2485-90. doi: 10.1111/j.1572-0241.2003.08699.x.
Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, Rinaldi L, Marfella R, Sasso FC. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Mol Sci. 2023 Jan 15;24(2):1703. doi: 10.3390/ijms24021703. PMID: 36675217; PMCID: PMC9865319.
Della Pepa G, Russo M, Vitale M, Carli F, Vetrani C, Masulli M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract (2021) 178:108984. doi: 10.1016/j.diabres.2021.108984
Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, et al. Anti-NASH drug development hitches a lift on PPAR agonism. Cells (2019) 9(1):37. doi: 10.3390/cells9010037
Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–1556. doi:10.1001/jama.2011.1437
Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol. Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102.
Trujillo J.M., Nuffer W., Smith B.A. GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 2021;12:2042018821997320. doi: 10.1177/2042018821997320.